Clinical Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in Kenya.

The BD FACSPresto™ Near-Patient CD4 Counter was developed to expand HIV/AIDS management in resource-limited settings. It measures absolute CD4 counts (AbsCD4), percent CD4 (%CD4), and hemoglobin (Hb) from a single drop of capillary or venous blood in approximately 23 minutes, with throughput of 10 s...

Full description

Bibliographic Details
Main Authors: Francis Angira, Benta Akoth, Paul Omolo, Valarie Opollo, Scott Bornheimer, Kevin Judge, Henok Tilahun, Beverly Lu, Imelda Omana-Zapata, Clement Zeh
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4970792?pdf=render
id doaj-de1c1abe9a8a4f9da6fdb411df60a7d4
record_format Article
spelling doaj-de1c1abe9a8a4f9da6fdb411df60a7d42020-11-25T00:08:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01118e015793910.1371/journal.pone.0157939Clinical Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in Kenya.Francis AngiraBenta AkothPaul OmoloValarie OpolloScott BornheimerKevin JudgeHenok TilahunBeverly LuImelda Omana-ZapataClement ZehThe BD FACSPresto™ Near-Patient CD4 Counter was developed to expand HIV/AIDS management in resource-limited settings. It measures absolute CD4 counts (AbsCD4), percent CD4 (%CD4), and hemoglobin (Hb) from a single drop of capillary or venous blood in approximately 23 minutes, with throughput of 10 samples per hour. We assessed the performance of the BD FACSPresto system, evaluating accuracy, stability, linearity, precision, and reference intervals using capillary and venous blood at KEMRI/CDC HIV-research laboratory, Kisumu, Kenya, and precision and linearity at BD Biosciences, California, USA.For accuracy, venous samples were tested using the BD FACSCalibur™ instrument with BD Tritest™ CD3/CD4/CD45 reagent, BD Trucount™ tubes, and BD Multiset™ software for AbsCD4 and %CD4, and the Sysmex™ KX-21N for Hb. Stability studies evaluated duration of staining (18-120-minute incubation), and effects of venous blood storage <6-24 hours post-draw. A normal cohort was tested for reference intervals. Precision covered multiple days, operators, and instruments. Linearity required mixing two pools of samples, to obtain evenly spaced concentrations for AbsCD4, total lymphocytes, and Hb.AbsCD4 and %CD4 venous/capillary (N = 189/ N = 162) accuracy results gave Deming regression slopes within 0.97-1.03 and R2 ≥0.96. For Hb, Deming regression results were R2 ≥0.94 and slope ≥0.94 for both venous and capillary samples. Stability varied within 10% 2 hours after staining and for venous blood stored less than 24 hours. Reference intervals results showed that gender-but not age-differences were statistically significant (p<0.05). Precision results had <3.5% coefficient of variation for AbsCD4, %CD4, and Hb, except for low AbsCD4 samples (<6.8%). Linearity was 42-4,897 cells/μL for AbsCD4, 182-11,704 cells/μL for total lymphocytes, and 2-24 g/dL for Hb.The BD FACSPresto system provides accurate, precise clinical results for capillary or venous blood samples and is suitable for near-patient CD4 testing.ClinicalTrials.gov NCT02396355.http://europepmc.org/articles/PMC4970792?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Francis Angira
Benta Akoth
Paul Omolo
Valarie Opollo
Scott Bornheimer
Kevin Judge
Henok Tilahun
Beverly Lu
Imelda Omana-Zapata
Clement Zeh
spellingShingle Francis Angira
Benta Akoth
Paul Omolo
Valarie Opollo
Scott Bornheimer
Kevin Judge
Henok Tilahun
Beverly Lu
Imelda Omana-Zapata
Clement Zeh
Clinical Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in Kenya.
PLoS ONE
author_facet Francis Angira
Benta Akoth
Paul Omolo
Valarie Opollo
Scott Bornheimer
Kevin Judge
Henok Tilahun
Beverly Lu
Imelda Omana-Zapata
Clement Zeh
author_sort Francis Angira
title Clinical Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in Kenya.
title_short Clinical Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in Kenya.
title_full Clinical Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in Kenya.
title_fullStr Clinical Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in Kenya.
title_full_unstemmed Clinical Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in Kenya.
title_sort clinical evaluation of the bd facspresto™ near-patient cd4 counter in kenya.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description The BD FACSPresto™ Near-Patient CD4 Counter was developed to expand HIV/AIDS management in resource-limited settings. It measures absolute CD4 counts (AbsCD4), percent CD4 (%CD4), and hemoglobin (Hb) from a single drop of capillary or venous blood in approximately 23 minutes, with throughput of 10 samples per hour. We assessed the performance of the BD FACSPresto system, evaluating accuracy, stability, linearity, precision, and reference intervals using capillary and venous blood at KEMRI/CDC HIV-research laboratory, Kisumu, Kenya, and precision and linearity at BD Biosciences, California, USA.For accuracy, venous samples were tested using the BD FACSCalibur™ instrument with BD Tritest™ CD3/CD4/CD45 reagent, BD Trucount™ tubes, and BD Multiset™ software for AbsCD4 and %CD4, and the Sysmex™ KX-21N for Hb. Stability studies evaluated duration of staining (18-120-minute incubation), and effects of venous blood storage <6-24 hours post-draw. A normal cohort was tested for reference intervals. Precision covered multiple days, operators, and instruments. Linearity required mixing two pools of samples, to obtain evenly spaced concentrations for AbsCD4, total lymphocytes, and Hb.AbsCD4 and %CD4 venous/capillary (N = 189/ N = 162) accuracy results gave Deming regression slopes within 0.97-1.03 and R2 ≥0.96. For Hb, Deming regression results were R2 ≥0.94 and slope ≥0.94 for both venous and capillary samples. Stability varied within 10% 2 hours after staining and for venous blood stored less than 24 hours. Reference intervals results showed that gender-but not age-differences were statistically significant (p<0.05). Precision results had <3.5% coefficient of variation for AbsCD4, %CD4, and Hb, except for low AbsCD4 samples (<6.8%). Linearity was 42-4,897 cells/μL for AbsCD4, 182-11,704 cells/μL for total lymphocytes, and 2-24 g/dL for Hb.The BD FACSPresto system provides accurate, precise clinical results for capillary or venous blood samples and is suitable for near-patient CD4 testing.ClinicalTrials.gov NCT02396355.
url http://europepmc.org/articles/PMC4970792?pdf=render
work_keys_str_mv AT francisangira clinicalevaluationofthebdfacsprestonearpatientcd4counterinkenya
AT bentaakoth clinicalevaluationofthebdfacsprestonearpatientcd4counterinkenya
AT paulomolo clinicalevaluationofthebdfacsprestonearpatientcd4counterinkenya
AT valarieopollo clinicalevaluationofthebdfacsprestonearpatientcd4counterinkenya
AT scottbornheimer clinicalevaluationofthebdfacsprestonearpatientcd4counterinkenya
AT kevinjudge clinicalevaluationofthebdfacsprestonearpatientcd4counterinkenya
AT henoktilahun clinicalevaluationofthebdfacsprestonearpatientcd4counterinkenya
AT beverlylu clinicalevaluationofthebdfacsprestonearpatientcd4counterinkenya
AT imeldaomanazapata clinicalevaluationofthebdfacsprestonearpatientcd4counterinkenya
AT clementzeh clinicalevaluationofthebdfacsprestonearpatientcd4counterinkenya
_version_ 1725414443650646016